Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances a novel, dual-inhibitor into Phase 3 for AKC, a chronic inflammatory eye disease with no FDA-approved treatment options.